{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:02:33Z","timestamp":1790276553446,"version":"4.1.0"},"reference-count":80,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic lymphocytic leukemia (CLL) is a malignancy of mature B cells that depend on host factors in the tissue microenvironment for survival and proliferation. In vitro, CLL cells rapidly undergo apoptosis unless microenvironmental factors are provided that support their survival. Signaling pathways activated in the microenvironment in vivo include the B-cell receptor (BCR) and NF-\u03baB pathways. Thus, CLL is a disease \u201caddicted to the host\u201d and is dependent on pathways that promote normal B-cell development, expansion, and survival; this is particularly true in the case of the BCR signaling cascade. Small-molecule inhibitors of kinases that are essential for BCR signal transduction abrogate the stimulating effects of the microenvironment on CLL cells. The orally administered tyrosine kinase inhibitors fostamatinib and ibrutinib and the phosphatidylinositol 3-kinase inhibitor GS-1101 have induced impressive responses in relapsed and refractory CLL patients, mostly with moderate side effects. Reductions in lymphadenopathy and splenomegaly are seen within weeks and are frequently accompanied by a transient rise in absolute lymphocyte count that is asymptomatic and probably the result of changes in CLL cell trafficking. This review discusses the biologic basis for kinase inhibitors as targeted therapy of CLL and summarizes the exciting early clinical experience with these agents.<\/jats:p>","DOI":"10.1182\/blood-2012-05-423194","type":"journal-article","created":{"date-parts":[[2012,8,9]],"date-time":"2012-08-09T06:18:50Z","timestamp":1344493130000},"page":"4684-4691","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":119,"title":["Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"120","author":[{"given":"Adrian","family":"Wiestner","sequence":"first","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111811301953800_B1","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2011.163","article-title":"Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia.","volume":"25","author":"Zhang","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"2019111811301953800_B2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia.","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111811301953800_B3","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.","volume":"109","author":"Wierda","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111811301953800_B4","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","article-title":"Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.","volume":"112","author":"Rassenti","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111811301953800_B5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111811301953800_B6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2796.2008.02030.x","article-title":"Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation.","volume":"264","author":"Ghia","year":"2008","journal-title":"J Intern Med"},{"key":"2019111811301953800_B7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/asheducation-2011.1.96","article-title":"Nurture versus nature: the microenvironment in chronic lymphocytic leukemia.","volume":"2011","author":"Burger","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"16","key":"2019111811301953800_B8","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies.","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111811301953800_B9","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3324\/haematol.2009.006676","article-title":"Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation.","volume":"94","author":"Deaglio","year":"2009","journal-title":"Haematologica"},{"issue":"5","key":"2019111811301953800_B10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction.","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"issue":"8","key":"2019111811301953800_B11","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"issue":"20","key":"2019111811301953800_B12","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/blood-2010-12-324210","article-title":"A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.","volume":"117","author":"Bagnara","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111811301953800_B13","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V98.10.3050","article-title":"Survival of leukemic B cells promoted by engagement of the antigen receptor.","volume":"98","author":"Bernal","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2019111811301953800_B14","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","article-title":"The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.","volume":"111","author":"Longo","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111811301953800_B15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2008.07475.x","article-title":"Expression and function of toll like receptors in chronic lymphocytic leukaemia cells.","volume":"144","author":"Muzio","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111811301953800_B16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2007-04-084756","article-title":"The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.","volume":"112","author":"Luqman","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111811301953800_B17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2006-06-027755","article-title":"BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.","volume":"109","author":"Endo","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111811301953800_B18","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3109\/10428194.2011.569962","article-title":"Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1.","volume":"52","author":"Herishanu","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"2019111811301953800_B19","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2009-07-233692","article-title":"Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.","volume":"115","author":"Buchner","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111811301953800_B20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","article-title":"B cell antigen receptor signaling 101.","volume":"41","author":"Dal Porto","year":"2004","journal-title":"Mol Immunol"},{"issue":"10","key":"2019111811301953800_B21","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ni.2094","article-title":"Malignant pirates of the immune system.","volume":"12","author":"Rui","year":"2011","journal-title":"Nat Immunol"},{"issue":"8","key":"2019111811301953800_B22","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1172\/JCI3009","article-title":"Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.","volume":"102","author":"Fais","year":"1998","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111811301953800_B23","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2004-01-0132","article-title":"Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia.","volume":"104","author":"Tobin","year":"2004","journal-title":"Blood"},{"issue":"19","key":"2019111811301953800_B24","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1182\/blood-2011-11-393694","article-title":"Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.","volume":"119","author":"Agathangelidis","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111811301953800_B25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.20040544","article-title":"Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia.","volume":"200","author":"Messmer","year":"2004","journal-title":"J Exp Med"},{"issue":"13","key":"2019111811301953800_B26","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1182\/blood-2008-06-162024","article-title":"Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.","volume":"112","author":"Chu","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111811301953800_B27","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/blood-2006-11-056648","article-title":"Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status.","volume":"109","author":"Mockridge","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111811301953800_B28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2007-09-111344","article-title":"Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy.","volume":"112","author":"Muzio","year":"2008","journal-title":"Blood"},{"issue":"7277","key":"2019111811301953800_B29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"4","key":"2019111811301953800_B30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2008.346","article-title":"Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.","volume":"23","author":"Gobessi","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"2019111811301953800_B31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","article-title":"B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.","volume":"114","author":"Quiroga","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111811301953800_B32","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1182\/blood-2011-07-367417","article-title":"Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.","volume":"119","author":"Paterson","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111811301953800_B33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2011-12-397158","article-title":"The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia.","volume":"120","author":"Le Roy","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111811301953800_B34","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2006-03-011759","article-title":"ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.","volume":"109","author":"Gobessi","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111811301953800_B35","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood-2004-05-1715","article-title":"ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia.","volume":"105","author":"Chen","year":"2005","journal-title":"Blood"},{"issue":"16","key":"2019111811301953800_B36","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia.","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111811301953800_B37","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/1074-7613(95)90126-4","article-title":"Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice.","volume":"3","author":"Nishizumi","year":"1995","journal-title":"Immunity"},{"issue":"33","key":"2019111811301953800_B38","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2019111811301953800_B39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2141.2010.08507.x","article-title":"Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.","volume":"153","author":"McCaig","year":"2011","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111811301953800_B40","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","article-title":"Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.","volume":"17","author":"Amrein","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111811301953800_B41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions.","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2019111811301953800_B42","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"2019111811301953800_B43","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2007-07-100115","article-title":"SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"issue":"23","key":"2019111811301953800_B44","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2010-03-275180","article-title":"The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.","volume":"116","author":"Suljagic","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111811301953800_B45","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1182\/blood-2008-05-158618","article-title":"Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.","volume":"113","author":"Young","year":"2009","journal-title":"Blood"},{"issue":"13","key":"2019111811301953800_B46","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"14","key":"2019111811301953800_B47","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","article-title":"An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.","volume":"363","author":"Weinblatt","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111811301953800_B48","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/leu.2012.24","article-title":"Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.","volume":"26","author":"Hoellenriegel","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2019111811301953800_B49","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.coi.2011.01.001","article-title":"Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation.","volume":"23","author":"Baracho","year":"2011","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"2019111811301953800_B50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/BJ20112092","article-title":"PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.","volume":"442","author":"So","year":"2012","journal-title":"Biochem J"},{"issue":"134","key":"2019111811301953800_B51","doi-asserted-by":"crossref","first-page":"ra60","DOI":"10.1126\/scisignal.2001104","article-title":"The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.","volume":"3","author":"Ramadani","year":"2010","journal-title":"Sci Signal"},{"issue":"3","key":"2019111811301953800_B52","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature B cell survival.","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"issue":"2","key":"2019111811301953800_B53","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111811301953800_B54","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2019111811301953800_B55","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111811301953800_B56","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111811301953800_B57","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1182\/blood-2008-06-165068","article-title":"Isoform-selective phosphoinositide 3\u2032-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.","volume":"113","author":"Niedermeier","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111811301953800_B58","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-11-2113","article-title":"ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism involving PI3K\/AKT inhibition and induction of oxidative stress.","volume":"18","author":"Chapman","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111811301953800_B59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling.","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"2019111811301953800_B60","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"21","key":"2019111811301953800_B61","first-page":"55","article-title":"CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110\u03b4, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia [abstract].","volume":"116","author":"Furman","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111811301953800_B62","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.6631","article-title":"Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia [abstract].","volume":"29","author":"Coutre","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111811301953800_B63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"issue":"29","key":"2019111811301953800_B64","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111811301953800_B65","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.","volume":"2","author":"Pan","year":"2007","journal-title":"Chem Med Chem"},{"issue":"11","key":"2019111811301953800_B66","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2019111811301953800_B67","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111811301953800_B68","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111811301953800_B69","first-page":"596","article-title":"The Bruton tyrosine kinase inhibitor, PCI-32765, inhibits activation and proliferation of human chronic lymphocytic leukemia cells in the NSG xenograph mouse model of the tissue microenvironment [abstract].","volume":"118","author":"Herman","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111811301953800_B70","first-page":"3485","article-title":"Clinical development of AVL-292: a potent, selective covalent Btk inhibitor for the treatment of B cell malignancies [abstract].","volume":"118","author":"Evans","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111811301953800_B71","article-title":"The BTK inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed\/refractory B-cell malignancies: final results from a Phase I study.","author":"Advani","year":"2011","journal-title":"Ann Oncol"},{"issue":"21","key":"2019111811301953800_B72","first-page":"983","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): follow-up of a Phase Ib\/II study [abstract].","volume":"118","author":"O'Brien","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111811301953800_B73","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.6507","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): interim results of a phase Ib\/II study [abstract].","volume":"30","author":"Byrd","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111811301953800_B74","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","article-title":"Novel targeted agents and the need to refine clinical end points in chronic lymphocytic keukemia.","volume":"30","author":"Cheson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111811301953800_B75","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111811301953800_B76","first-page":"974","article-title":"BH3 profiling demonstrates that restoration of apoptotic priming contributes to increased sensitivity to PI3K inhibition in stroma-exposed chronic lymphocytic leukemia cells [abstract].","volume":"118","author":"Davids","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"2019111811301953800_B77","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"issue":"16","key":"2019111811301953800_B78","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1182\/blood-2010-11-315705","article-title":"The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111811301953800_B79","first-page":"979","article-title":"Correlates of lenalidomide induced immune stimulation and response in CLL: analysis in patients on treatment [abstract].","volume":"118","author":"Aue","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"10","key":"2019111811301953800_B80","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/cncr.25748","article-title":"Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.","volume":"117","author":"Chanan-Khan","year":"2011","journal-title":"Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/24\/4684\/1361122\/zh805012004684.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/24\/4684\/1361122\/zh805012004684.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T11:50:15Z","timestamp":1594554615000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/24\/4684\/31002\/Emerging-role-of-kinasetargeted-strategies-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,6]]},"references-count":80,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2012,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-05-423194","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,6]]}}}